|
US2631173A
(en)
|
1949-01-04 |
1953-03-10 |
Phillips Petroleum Co |
Production of cyclooctadiene
|
|
IL54795A
(en)
|
1978-05-26 |
1980-10-26 |
Yeda Res & Dev |
Analgesic compositions comprising substituted bicyclic and spiroaliphatic amines and certain novel compounds of these types
|
|
EP0425491B1
(en)
|
1988-03-02 |
1994-07-20 |
The Uab Research Foundation |
Reversible mechanochemical engines comprised of bioelastomers capable of modulable inverse temperature transitions for the interconversion of chemical and mechanical work
|
|
WO1991004753A1
(en)
|
1989-10-02 |
1991-04-18 |
Cetus Corporation |
Conjugates of antisense oligonucleotides and therapeutic uses thereof
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
US6255455B1
(en)
|
1996-10-11 |
2001-07-03 |
The Trustees Of The University Of Pennsylvania |
Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
|
|
GB9722131D0
(en)
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
|
US7064142B2
(en)
|
2000-02-22 |
2006-06-20 |
Banyu Pharmaceutical, Co., Ltd. |
Imidazonline compounds
|
|
WO2001083740A2
(en)
|
2000-05-04 |
2001-11-08 |
Avi Biopharma, Inc. |
Splice-region antisense composition and method
|
|
EP1191097A1
(en)
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
|
JP2002253259A
(ja)
|
2001-03-02 |
2002-09-10 |
Bio Applied Systems:Kk |
抗ビスフェノールａ抗体をコードする遺伝子、組換えタンパク質およびその製造方法
|
|
US20040063654A1
(en)
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
|
US7241444B2
(en)
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
|
AU2003207708A1
(en)
|
2002-02-20 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of map kinase genes
|
|
EP1518120A4
(en)
|
2002-03-11 |
2008-08-13 |
Momenta Pharmaceuticals Inc |
ANALYSIS OF SULFATE POLYSACCHARIDES
|
|
US7902160B2
(en)
|
2002-11-25 |
2011-03-08 |
Masafumi Matsuo |
ENA nucleic acid drugs modifying splicing in mRNA precursor
|
|
US20040191243A1
(en)
|
2002-12-13 |
2004-09-30 |
Bei Chen |
System and method for stabilizing antibodies with histidine
|
|
EP1572660B1
(en)
|
2002-12-20 |
2011-01-26 |
X-Ceptor Therapeutics, Inc. |
Isoquinolinone derivatives and their use as therapeutic agents
|
|
AU2003225410A1
(en)
|
2003-03-21 |
2004-10-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
WO2005058244A2
(en)
|
2003-12-15 |
2005-06-30 |
Alexion Pharmaceuticals, Inc. |
Novel anti-dc-sign antibodies
|
|
WO2005111211A2
(en)
|
2004-05-14 |
2005-11-24 |
Rosetta Genomics Ltd. |
Micronas and uses thereof
|
|
USRE48960E1
(en)
|
2004-06-28 |
2022-03-08 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
|
PL1766010T3
(pl)
|
2004-06-28 |
2011-07-29 |
Univ Western Australia |
Antysensowne oligonukleotydy do indukcji pominięcia egzonu i sposoby ich zastosowania
|
|
WO2006022688A1
(en)
|
2004-08-06 |
2006-03-02 |
Applera Corporation |
Diagnosis of pancreatic cancer by using pancreatic targets
|
|
FR2874384B1
(fr)
|
2004-08-17 |
2010-07-30 |
Genethon |
Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables
|
|
US8431558B2
(en)
|
2004-11-01 |
2013-04-30 |
The Regents Of The University Of California |
Compositions and methods for modification of biomolecules
|
|
EP1812031B1
(en)
|
2004-11-01 |
2015-06-24 |
The Regents of the University of California |
Compositions and methods for modification of biomolecules
|
|
US20120122801A1
(en)
|
2005-01-05 |
2012-05-17 |
Prosensa B.V. |
Mannose-6-phosphate receptor mediated gene transfer into muscle cells
|
|
US20060252107A1
(en)
|
2005-02-22 |
2006-11-09 |
Acucela, Inc. |
Compositions and methods for diagnosing and treating retinal diseases
|
|
US7736647B2
(en)
|
2005-06-15 |
2010-06-15 |
Monoclonal Antibodies Therapeutics |
Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
|
|
WO2008029281A2
(en)
|
2006-02-10 |
2008-03-13 |
Invitrogen Corporation |
Labeling and detection of post translationally modified proteins
|
|
US8859752B2
(en)
|
2006-04-18 |
2014-10-14 |
The Trustees Of The University Of Pennsylvania |
SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP)
|
|
EP1857548A1
(en)
|
2006-05-19 |
2007-11-21 |
Academisch Ziekenhuis Leiden |
Means and method for inducing exon-skipping
|
|
WO2008073300A2
(en)
|
2006-12-08 |
2008-06-19 |
Lexicon Pharmaceuticals, Inc. |
Monoclonal antibodies against angptl3
|
|
RS56743B1
(sr)
|
2007-08-21 |
2018-03-30 |
Amgen Inc |
Humani c-fms antigen vezujući proteini
|
|
USRE48468E1
(en)
|
2007-10-26 |
2021-03-16 |
Biomarin Technologies B.V. |
Means and methods for counteracting muscle disorders
|
|
EP2203173B1
(en)
|
2007-10-26 |
2015-12-23 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
US20110130346A1
(en)
|
2008-05-30 |
2011-06-02 |
Isis Innovation Limited |
Peptide conjugates for delvery of biologically active compounds
|
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
|
CN105779453A
(zh)
|
2008-10-24 |
2016-07-20 |
萨雷普塔治疗公司 |
用于dmd的多外显子跳跃组合物
|
|
PT2344637E
(pt)
|
2008-10-27 |
2015-03-23 |
Academisch Ziekenhuis Leiden |
Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne
|
|
EP2421971B1
(en)
|
2009-04-24 |
2016-07-06 |
BioMarin Technologies B.V. |
Oligonucleotide comprising an inosine for treating dmd
|
|
WO2010129861A2
(en)
|
2009-05-08 |
2010-11-11 |
Curna, Inc. |
Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
|
|
FR2947269B1
(fr)
|
2009-06-29 |
2013-01-18 |
Sanofi Aventis |
Nouveaux composes anticancereux
|
|
WO2011036640A2
(en)
|
2009-09-24 |
2011-03-31 |
Cellectis |
Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
|
|
BR122023023194A2
(pt)
|
2009-11-12 |
2023-12-26 |
The University Of Western Australia |
Oligonucleotídeo antissentido, composição e respectivo uso
|
|
WO2011078797A2
(en)
|
2009-12-22 |
2011-06-30 |
Singapore Health Services Pte. Ltd |
Antisense oligonucleotides and uses threreof
|
|
US8734799B2
(en)
|
2010-04-13 |
2014-05-27 |
The Regents Of The University Of California |
Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer
|
|
WO2011130598A1
(en)
|
2010-04-15 |
2011-10-20 |
Spirogen Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
EP2894142B1
(en)
|
2010-04-27 |
2019-06-12 |
SynAffix B.V. |
Fused cyclooctyne compounds and their use in metal-free click reactions
|
|
KR102182663B1
(ko)
|
2010-05-28 |
2020-11-25 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
|
|
IT1400425B1
(it)
|
2010-06-08 |
2013-05-31 |
Amsterdam Molecular Therapeutics Bv |
Modified snrnas for use in therapy.
|
|
JP5913307B2
(ja)
|
2010-07-12 |
2016-04-27 |
コヴェックス・テクノロジーズ・アイルランド・リミテッド |
多機能性抗体複合体
|
|
EP3489360A3
(en)
|
2010-07-19 |
2019-08-28 |
Ionis Pharmaceuticals, Inc. |
Modulation of nuclear-retained rna
|
|
TWI541024B
(zh)
|
2010-09-01 |
2016-07-11 |
日本新藥股份有限公司 |
反義核酸
|
|
EP2426203B1
(en)
|
2010-09-02 |
2016-07-13 |
Université de Mons |
Agents useful in treating facioscapulohumeral muscular dystrophy
|
|
WO2012075037A1
(en)
|
2010-11-30 |
2012-06-07 |
Genentech, Inc. |
Low affinity blood brain barrier receptor antibodies and uses therefor
|
|
PE20170917A1
(es)
|
2010-12-20 |
2017-07-12 |
Genentech Inc |
Anticuerpos anti-mesotelina e inmunoconjugados
|
|
CA2826836A1
(en)
|
2011-02-08 |
2012-08-16 |
The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center |
Antisense oligonucleotides
|
|
BR112013024717A2
(pt)
|
2011-04-07 |
2017-08-08 |
Genentech Inc |
anticorpo isolado, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, método de tratar um indivíduo que tem câncer e método de inibir proliferação celular em um indivíduo
|
|
CN107080847A
(zh)
|
2011-06-24 |
2017-08-22 |
森彻斯有限公司 |
细胞外靶向药物缀合物
|
|
BR112014003999A2
(pt)
|
2011-08-23 |
2017-06-13 |
Roche Glycart Ag |
anticorpo isolado que se liga a um epítopo próximo da membrana de mcsp humano, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de indivíduos portadores de câncer, método de undução da lise celular em indivíduos e teste imuno-histoquímico de mcsp
|
|
US20130066063A1
(en)
|
2011-09-09 |
2013-03-14 |
John Cooke Hodges |
Bicyclo[6.1.0]non-4-yne regents for chemical modification of oligonucleotides
|
|
CA2858347C
(en)
|
2011-12-05 |
2020-07-07 |
New York University |
V1v2 immunogens
|
|
EP2788087A4
(en)
|
2011-12-06 |
2015-08-26 |
Ohio State Innovation Foundation |
Non-ionic, low-osmolar contrast agents for the administration of antisense oligonucleotides and the treatment of diseases
|
|
CA3132111A1
(en)
|
2011-12-28 |
2013-07-04 |
Nippon Shinyaku Co., Ltd. |
Antisense nucleic acids for skipping of exon 55 of human dystrophin gene
|
|
US20130177579A1
(en)
|
2012-01-06 |
2013-07-11 |
Bioalliance C.V. |
Anti-transferrin receptor antibodies and methods using same
|
|
JP6413127B2
(ja)
|
2012-01-09 |
2018-10-31 |
コヴェックス・テクノロジーズ・アイルランド・リミテッド |
変異抗体およびそのコンジュゲーション
|
|
CN118581086A
(zh)
|
2012-01-27 |
2024-09-03 |
比奥马林技术公司 |
用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
|
|
RU2014138474A
(ru)
|
2012-02-24 |
2016-04-10 |
СтемСентРкс, Инк. |
Новые модуляторы и способы применения
|
|
WO2013138662A1
(en)
|
2012-03-16 |
2013-09-19 |
4S3 Bioscience, Inc. |
Antisense conjugates for decreasing expression of dmpk
|
|
EP3604536B1
(en)
|
2012-04-23 |
2024-05-29 |
Vico Therapeutics B.V. |
Rna modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders
|
|
EP2870246B1
(en)
|
2012-07-03 |
2019-09-11 |
BioMarin Technologies B.V. |
Oligonucleotide for the treatment of muscular dystrophy patients
|
|
EP2684892A1
(en)
|
2012-07-13 |
2014-01-15 |
Association Française contre les Myopathies |
Compositions and methods for duchenne muscular dystrophy gene therapy
|
|
ES2791778T3
(es)
|
2012-08-01 |
2020-11-05 |
Ikaika Therapeutics Llc |
Mitigación del daño tisular y la fibrosis a través de anticuerpos anti-LTBP4
|
|
CA2884608C
(en)
|
2012-09-14 |
2025-05-20 |
Translate Bio Ma, Inc. |
MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS
|
|
ES2659270T5
(en)
|
2012-10-23 |
2026-02-11 |
Synaffix Bv |
Modified antibody, antibody-conjugate and process for the preparation thereof
|
|
AU2012395148B2
(en)
|
2012-11-24 |
2016-10-27 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
|
MX2015010682A
(es)
|
2013-02-22 |
2016-05-31 |
Stemcentrx Inc |
Nuevos conjugados de anticuerpos y usos de los mismos.
|
|
EA202090946A3
(ru)
|
2013-03-14 |
2021-07-30 |
Сарепта Терапьютикс, Инк. |
Композиции, обеспечивающие пропускание экзонов, для лечения мышечной дистрофии
|
|
HRP20190382T1
(hr)
|
2013-03-14 |
2019-04-19 |
Sarepta Therapeutics, Inc. |
Pripravci koji preskaču ekson za liječenje mišićne distrofije
|
|
NZ631289A
(en)
|
2013-03-15 |
2017-08-25 |
Sarepta Therapeutics Inc |
Improved compositions for treating muscular dystrophy
|
|
EA038367B1
(ru)
|
2013-05-20 |
2021-08-16 |
Дженентек, Инк. |
АНТИТЕЛА ПРОТИВ РЕЦЕПТОРА ТРАНСФЕРРИНА (TfR) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ
|
|
WO2014189370A1
(en)
|
2013-05-24 |
2014-11-27 |
Stichting Katholieke Universiteit |
Substituted azadibenzocyclooctyne compounds and their use in metal-free click reactions
|
|
ES3029138T3
(en)
|
2013-06-05 |
2025-06-23 |
Univ Duke |
Rna-guided gene editing and gene regulation
|
|
RU2016111137A
(ru)
|
2013-08-28 |
2017-10-03 |
ЭББВИ СТЕМСЕНТРКС ЭлЭлСи |
Сконструированные конъюгаты против dll3 и способы применения
|
|
AU2014321211A1
(en)
|
2013-09-23 |
2016-05-05 |
President And Fellows Of Harvard College |
Allele-specific RNA silencing for the treatment of hypertrophic cardiomyopathy
|
|
US9987373B2
(en)
|
2013-10-14 |
2018-06-05 |
Synaffix B.V. |
Modified glycoprotein, protein-conjugate and process for the preparation thereof
|
|
EP3057618B1
(en)
|
2013-10-14 |
2022-12-14 |
SynAffix B.V. |
Glycoengineered antibody, antibody-conjugate and methods for their preparation
|
|
WO2015073848A1
(en)
|
2013-11-14 |
2015-05-21 |
Shehadeh Lina A |
Methods and compositions employing an osteopontin aptamer to deliver nucleic acids into smooth muscle, endothelial, cardiac and progenitor/stem cells
|
|
WO2015112016A1
(en)
|
2014-01-24 |
2015-07-30 |
Synaffix B.V. |
Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
|
|
EP3097079B1
(en)
|
2014-01-24 |
2021-05-12 |
SynAffix B.V. |
Process for the cycloaddition of a hetero(aryl) 1,3-dipole compound with a (hetero)cycloalkyne
|
|
WO2015134365A2
(en)
|
2014-03-03 |
2015-09-11 |
Acharjee Sujata |
Chimeric dystrophin-vsv-g-protein to treat dystrophinopathies
|
|
RU2730681C2
(ru)
|
2014-03-12 |
2020-08-24 |
Ниппон Синяку Ко., Лтд. |
Антисмысловые нуклеиновые кислоты
|
|
AR099625A1
(es)
|
2014-03-21 |
2016-08-03 |
Lilly Co Eli |
Anticuerpos de il-21
|
|
CN103882024A
(zh)
|
2014-04-21 |
2014-06-25 |
石河子大学 |
一种RNAi干扰片段、RNAi干扰载体及其应用
|
|
JP6750148B2
(ja)
|
2014-04-25 |
2020-09-02 |
公益財団法人野口研究所 |
糖鎖切断抗体の製造方法及び均一糖鎖抗体
|
|
EP3146050B1
(en)
|
2014-05-23 |
2020-08-12 |
Genzyme Corporation |
Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides
|
|
AU2015277924B2
(en)
|
2014-06-17 |
2021-02-25 |
National Center Of Neurology And Psychiatry |
Antisense nucleic acids
|
|
KR20170030648A
(ko)
|
2014-08-04 |
2017-03-17 |
시나픽스 비.브이. |
베타-(1,4)-n-아세틸갈락토오스아미닐트랜스퍼라아제, 또는 이의 돌연변이체를 이용한 당 단백질의 변형 방법
|
|
GB201416960D0
(en)
|
2014-09-25 |
2014-11-12 |
Antikor Biopharma Ltd |
Biological materials and uses thereof
|
|
US9714288B2
(en)
|
2014-09-30 |
2017-07-25 |
The Regents Of The University Of California |
Antisense compounds and uses thereof
|
|
ES2740907T3
(es)
|
2014-10-03 |
2020-02-07 |
Synaffix Bv |
Enlazador de sulfamida, conjugados de los mismos y métodos de preparación
|
|
WO2016077840A2
(en)
|
2014-11-14 |
2016-05-19 |
Ossianix, Inc. |
TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS
|
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック， インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
|
PH12017500935A1
(en)
|
2014-11-21 |
2017-11-27 |
Merck Sharp & Dohme |
Insulin receptor partial agonists
|
|
HUE038511T2
(hu)
|
2015-04-23 |
2018-10-29 |
Synaffix Bv |
(1,4)-N-acetil-galaktóz-aminil-transzferáz vagy (1,4)-N-acetil-galaktóz-aminil-transzferázból származó glikoziltranszferázt alkalmazó, glikoprotein módosítására szolgáló eljárás
|
|
IL310251A
(en)
|
2015-05-04 |
2024-03-01 |
Cytomx Therapeutics Inc |
Anti-cd71 antibodies, activatable anti-cd71 antibodies, compositions comprising same and uses thereof
|
|
CN114681621B
(zh)
|
2015-05-19 |
2024-08-06 |
萨勒普塔医疗公司 |
肽寡核苷酸缀合物
|
|
WO2016205641A2
(en)
|
2015-06-17 |
2016-12-22 |
Research Institute At Nationwide Children's Hospital |
Respiratory syncytial virus having cleavage-resistant g protein and related materials and methods
|
|
KR20250073514A
(ko)
|
2015-06-24 |
2025-05-27 |
제이씨알 파마 가부시키가이샤 |
혈액뇌관문을 통과하는 항인간 트랜스페린 수용체 항체
|
|
EP3325509B1
(en)
|
2015-07-22 |
2020-12-16 |
Inatherys |
Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders
|
|
HRP20201125T1
(hr)
|
2015-09-15 |
2020-10-30 |
Nippon Shinyaku Co., Ltd. |
Antisens nukleinska kiselina
|
|
US20180265859A1
(en)
|
2015-09-23 |
2018-09-20 |
UNIVERSITé LAVAL |
Modification of the dystrophin gene and uses thereof
|
|
WO2017062835A2
(en)
|
2015-10-09 |
2017-04-13 |
Sarepta Therapeutics, Inc. |
Compositions and methods for treating duchenne muscular dystrophy and related disorders
|
|
EP3359523A4
(en)
|
2015-10-09 |
2019-07-24 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND METHOD THEREFOR
|
|
KR20250133801A
(ko)
|
2015-12-08 |
2025-09-08 |
리제너론 파마슈티칼스 인코포레이티드 |
효소 내재화 조성물 및 방법
|
|
FR3044926B1
(fr)
|
2015-12-09 |
2020-01-31 |
Genethon |
Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine
|
|
MX2018007451A
(es)
|
2015-12-18 |
2018-11-09 |
Eisai R&D Man Co Ltd |
Inmunoglobulinas conjugadas con lisina c-terminal.
|
|
US10874746B2
(en)
|
2016-02-08 |
2020-12-29 |
Synaffix B.V. |
Sulfamide linkers for use in bioconjugates
|
|
IL260983B
(en)
|
2016-02-19 |
2022-07-01 |
Genisphere Llc |
Nucleic acid carriers and methods of medical use
|
|
LT3433280T
(lt)
|
2016-03-22 |
2023-07-10 |
F. Hoffmann-La Roche Ag |
Proteazės aktyvuojamos t ląstelei bispecifinės molekulės
|
|
KR102775461B1
(ko)
|
2016-04-01 |
2025-02-28 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩타이드 조성물 및 이의 용도
|
|
FR3049951A1
(fr)
|
2016-04-12 |
2017-10-13 |
Univ Rabelais Francois |
Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose
|
|
US20190249173A1
(en)
|
2016-05-04 |
2019-08-15 |
Chandra Vargeese |
Methods and compositions of biologically active agents
|
|
EP3922260A3
(en)
|
2016-05-24 |
2022-06-15 |
Merck Sharp & Dohme Corp. |
Insulin receptor partial agonists and glp-1 analogues
|
|
MX383656B
(es)
|
2016-05-24 |
2025-03-14 |
Sarepta Therapeutics Inc |
Procesos para preparar oligómeros de morfolino fosforodiamidato.
|
|
US11013757B2
(en)
|
2016-06-03 |
2021-05-25 |
Wave Life Sciences Ltd. |
Oligonucleotides, compositions and methods thereof
|
|
US20190240346A1
(en)
|
2016-06-20 |
2019-08-08 |
Genahead Bio, Inc. |
Antibody-drug conjugate
|
|
US20180028554A1
(en)
|
2016-07-05 |
2018-02-01 |
Biomarin Technologies B.V. |
Oligomers Having Bicyclic Scaffold Moeities
|
|
US20190330626A1
(en)
*
|
2016-07-15 |
2019-10-31 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for use in dystrophin transcript
|
|
EP4275747A3
(en)
|
2016-07-19 |
2024-01-24 |
Duke University |
Therapeutic applications of cpf1-based genome editing
|
|
MX2019005671A
(es)
|
2016-11-16 |
2020-07-20 |
Academisch Ziekenhuis Leiden |
Sustancias para direccionar diversos organos o tejidos seleccionados.
|
|
US10947540B2
(en)
|
2016-11-29 |
2021-03-16 |
Association Institut De Myologie |
Allele-specific silencing therapy for Dynamin 2-related diseases
|
|
CN110382695A
(zh)
|
2016-11-28 |
2019-10-25 |
得克萨斯州大学系统董事会 |
通过crispr/cpf1介导的基因编辑来预防肌营养不良
|
|
WO2018107003A1
(en)
|
2016-12-08 |
2018-06-14 |
The Board Of Regents Of The University Of Texas System |
Dmd reporter models containing humanized duschene muscular dystrophy mutations
|
|
CN117298290A
(zh)
|
2016-12-19 |
2023-12-29 |
萨勒普塔医疗公司 |
用于肌肉萎缩症的外显子跳跃寡聚体缀合物
|
|
NZ752703A
(en)
|
2016-12-26 |
2022-09-30 |
Japan Chem Res |
Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
|
|
JOP20190166A1
(ar)
|
2017-01-05 |
2019-07-02 |
Univ Texas |
استراتيجية مثلى من أجل تعديلات تخطي إكسون باستخدام crispr/cas9 مع متواليات توجيه ثلاثي
|
|
CN110381980A
(zh)
|
2017-01-06 |
2019-10-25 |
艾维迪提生物科学有限责任公司 |
核酸-多肽组合物以及诱导外显子跳读的方法
|
|
EP3574018A4
(en)
|
2017-01-27 |
2020-10-07 |
Silverback Therapeutics, Inc. |
CONJUGATES TARGETING TUMORS AND THEIR METHODS OF USE
|
|
ES3065816T3
(en)
|
2017-06-07 |
2026-05-08 |
Regeneron Pharma |
Compositions and methods for internalizing enzymes
|
|
EP3638699A1
(en)
|
2017-06-16 |
2020-04-22 |
Eli Lilly and Company |
Engineered antibody compounds and conjugates thereof
|
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
|
EA201991450A1
(ru)
|
2017-09-22 |
2019-12-30 |
Сарепта Терапьютикс, Инк. |
Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
|
|
MA50269A
(fr)
|
2017-09-22 |
2020-07-29 |
Avidity Biosciences Inc |
Compositions d'acides nucléiques-polypeptides et méthodes d'induction de saut d'exon
|
|
JP2020536060A
(ja)
|
2017-09-28 |
2020-12-10 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを処置するための併用療法
|
|
EP3687577A1
(en)
|
2017-09-28 |
2020-08-05 |
Sarepta Therapeutics, Inc. |
Combination therapies for treating muscular dystrophy
|
|
US11110180B2
(en)
|
2017-10-04 |
2021-09-07 |
Avidity Biosciences Inc. |
Nucleic acid-polypeptide compositions and uses thereof
|
|
WO2019079637A2
(en)
|
2017-10-18 |
2019-04-25 |
Sarepta Therapeutics, Inc. |
ANTISENSE OLIGOMERIC COMPOUNDS
|
|
US20210032622A1
(en)
|
2017-11-09 |
2021-02-04 |
Crispr Therapeutics Ag |
Self-inactivating (sin) crispr/cas or crispr/cpf1 systems and uses thereof
|
|
CN118638788A
(zh)
|
2017-12-06 |
2024-09-13 |
艾维迪提生物科学公司 |
治疗肌萎缩和强直性肌营养不良的组合物和方法
|
|
CN108220418B
(zh)
|
2017-12-29 |
2018-11-09 |
东莞博奥木华基因科技有限公司 |
基于多重pcr捕获技术的杜氏/贝氏肌营养不良症的检测试剂盒及方法
|
|
WO2019136180A2
(en)
|
2018-01-04 |
2019-07-11 |
Avidity Biosciences Llc |
Heteroduplex nucleic acid molecules and uses thereof
|
|
EP3735462A1
(en)
|
2018-01-05 |
2020-11-11 |
The Board of Regents of The University of Texas System |
Therapeutic crispr/cas9 compositions and methods of use
|
|
KR20200116933A
(ko)
|
2018-01-31 |
2020-10-13 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
인간 심근세포에서 디스트로핀 돌연변이를 교정하기 위한 조성물 및 방법
|
|
SG11202006433PA
(en)
|
2018-02-05 |
2020-08-28 |
Jcr Pharmaceuticals Co Ltd |
Method for delivering drug to muscle
|
|
CN112040985A
(zh)
|
2018-02-07 |
2020-12-04 |
瑞泽恩制药公司 |
用于递送治疗性蛋白质的方法和组合物
|
|
IL277889B2
(en)
|
2018-04-12 |
2025-01-01 |
Wave Life Sciences Ltd |
Oligonucleotide preparations and methods of using them
|
|
EP3784248A4
(en)
|
2018-04-26 |
2022-08-10 |
Sarepta Therapeutics, Inc. |
EXON-SKIPPING OLIGOMERS AND OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
|
|
WO2019215175A1
(en)
|
2018-05-08 |
2019-11-14 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
|
SG11202010131QA
(en)
|
2018-05-11 |
2020-11-27 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods of use thereof
|
|
SG11202010841QA
(en)
|
2018-05-11 |
2020-11-27 |
Alpha Anomeric Sas |
Oligonucleotides conjugates comprising 7'-5'-alpha-anomeric-bicyclic sugar nucleosides
|
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
JP2021526796A
(ja)
|
2018-06-13 |
2021-10-11 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーに対するエクソンスキッピングオリゴマー
|
|
WO2019246480A1
(en)
|
2018-06-21 |
2019-12-26 |
The Board Of Regents Of The University Of Texas System |
Correction of dystrophin exon 43, exon 45, or exon 52 deletions in duchenne muscular dystrophy
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
MX2021001282A
(es)
|
2018-08-02 |
2021-07-15 |
Dyne Therapeutics Inc |
Complejos dirigidos al músculo y sus usos.
|
|
US20220378934A1
(en)
|
2018-08-02 |
2022-12-01 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof in treating muscle atrophy
|
|
US20210308274A1
(en)
|
2018-08-02 |
2021-10-07 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating friedreich's ataxia
|
|
US20210322562A1
(en)
|
2018-08-02 |
2021-10-21 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating centronuclear myopathy
|
|
CA3108287A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US11168141B2
(en)
|
2018-08-02 |
2021-11-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
EA202190418A1
(ru)
|
2018-08-02 |
2021-06-23 |
Дайн Терапьютикс, Инк. |
Мышечно-специфические комлексы и их применение в лечении прогрессирующей оссифицирующей фибродисплазии
|
|
CA3108285A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating pompe disease
|
|
JP7611825B2
(ja)
|
2018-08-02 |
2025-01-10 |
ダイン セラピューティクス，インコーポレーテッド |
ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
|
|
US12370264B1
(en)
|
2018-08-02 |
2025-07-29 |
Dyne Therapeutics, Inc. |
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
|
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
EP3829594A4
(en)
|
2018-08-02 |
2022-05-11 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
|
|
US20220193250A1
(en)
|
2018-08-02 |
2022-06-23 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
CN109306375A
(zh)
|
2018-10-16 |
2019-02-05 |
上海瀚垚生物医学科技有限公司 |
EvaGreen法数字PCR检测DMD拷贝数变异的引物、检测试剂盒及其检测方法
|
|
IT201800009682A1
(it)
|
2018-10-22 |
2020-04-22 |
Ice Spa |
Coniugati di acidi biliari e loro derivati per la veicolazione di molecole attive
|
|
WO2020094670A1
(en)
|
2018-11-05 |
2020-05-14 |
Synaffix B.V. |
Antibody-conjugates for targeting of tumours expressing trop-2
|
|
CN113383078A
(zh)
|
2018-12-06 |
2021-09-10 |
波涛生命科学有限公司 |
寡核苷酸组合物及其方法
|
|
IL319265A
(en)
|
2018-12-21 |
2025-04-01 |
Avidity Biosciences Inc |
Anti-transferrin receptor antibodies and their uses
|
|
AU2019419494B2
(en)
|
2018-12-31 |
2026-03-26 |
Research Institute At Nationwide Children's Hospital |
DUX4 RNA silencing using RNA targeting CRISPR-Cas13b
|
|
SG11202108757XA
(en)
|
2019-03-28 |
2021-10-28 |
Sarepta Therapeutics Inc |
Methods for treating muscular dystrophy with casimersen
|
|
WO2020209285A1
(ja)
|
2019-04-08 |
2020-10-15 |
国立大学法人東京医科歯科大学 |
筋疾患治療用医薬組成物
|
|
US20220193246A1
(en)
|
2019-04-18 |
2022-06-23 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
|
CA3137715A1
(en)
|
2019-04-25 |
2020-10-29 |
Avidity Biosciences, Inc. |
Nucleic acid compositions and methods of multi-exon skipping
|
|
CA3142283A1
(en)
|
2019-06-06 |
2020-12-10 |
Avidity Biosciences, Inc. |
Nucleic acid-polypeptide compositions and uses thereof
|
|
US12006499B2
(en)
|
2019-06-06 |
2024-06-11 |
Avidity Biosciences, Inc. |
Una amidites and uses thereof
|
|
CN114025805B
(zh)
|
2019-06-07 |
2025-01-24 |
达因疗法公司 |
制备蛋白质-寡核苷酸复合物的方法
|
|
JP2022536495A
(ja)
|
2019-06-19 |
2022-08-17 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを治療する方法
|
|
WO2021003573A1
(en)
|
2019-07-09 |
2021-01-14 |
The Governors Of The University Of Alberta |
Exons 45-55 skipping using mutation-tailored cocktails of antisense morpholinos in the dmd gene
|
|
EP4023673A4
(en)
|
2019-10-10 |
2023-03-15 |
Suzhou Qin Pharmaceuticals Co., Ltd. |
ANTI-BCMA HUMANIZED MONOCLONAL ANTIBODY WITH HUMAN-MONKEY CROSS-REACTIVITY
|
|
WO2021076856A1
(en)
|
2019-10-18 |
2021-04-22 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
WO2021108640A1
(en)
|
2019-11-27 |
2021-06-03 |
Dtx Pharma, Inc. |
Compounds and methods for the treatment of duchenne muscular dystrophy
|
|
CN115335062A
(zh)
|
2020-01-10 |
2022-11-11 |
达因疗法公司 |
肌肉靶向复合物及其用于调节与肌肉健康相关的基因的用途
|
|
US20230203180A1
(en)
|
2020-01-10 |
2023-06-29 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
|
|
WO2021142217A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Thereapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of milck1
|
|
IL294479A
(en)
|
2020-01-10 |
2022-09-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and their uses for the treatment of myotonic dystrophy
|
|
KR20220125802A
(ko)
|
2020-01-10 |
2022-09-14 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도
|
|
WO2021142331A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease
|
|
CA3163608A1
(en)
|
2020-01-10 |
2021-07-15 |
Romesh R. Subramanian |
Muscle-targeting complexes and uses thereof
|
|
WO2021142260A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of acvr1
|
|
US20230088865A1
(en)
|
2020-01-10 |
2023-03-23 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
WO2021142269A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy
|
|
EP4093773A4
(en)
|
2020-01-24 |
2024-02-28 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETED COMPLEXES AND THEIR USE FOR THE TREATMENT OF MUSCLE ATROPHY
|
|
US12624120B2
(en)
|
2020-01-31 |
2026-05-12 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor (TfR) antibody and uses thereof
|
|
WO2021154476A1
(en)
|
2020-01-31 |
2021-08-05 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor (tfr) antibody and uses thereof
|
|
WO2021195469A1
(en)
|
2020-03-27 |
2021-09-30 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle dystrophy
|
|
WO2021226107A1
(en)
|
2020-05-05 |
2021-11-11 |
Avidity Biosciences, Inc. |
Compositions and methods of treating pompe disease
|
|
IL299663A
(en)
|
2020-07-23 |
2023-03-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and their uses for the treatment of myotonic dystrophy
|
|
WO2022020105A1
(en)
|
2020-07-23 |
2022-01-27 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor (tfr) antibody and uses thereof
|
|
AU2021313058A1
(en)
|
2020-07-23 |
2023-03-30 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof
|
|
CN116348139A
(zh)
|
2020-07-23 |
2023-06-27 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗面肩肱型肌营养不良的用途
|
|
US20230346966A1
(en)
|
2020-07-23 |
2023-11-02 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof in treating muscle atrophy
|
|
US20230285586A1
(en)
|
2020-07-23 |
2023-09-14 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
EP4208173A4
(en)
|
2020-09-03 |
2025-11-26 |
Dyne Therapeutics Inc |
PROCESSES FOR PREPARING PROTEIN-OLIGONUCLEOTIC COMPLEXES
|
|
AU2021342155A1
(en)
|
2020-09-11 |
2023-04-13 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use
|
|
US20240100177A1
(en)
|
2020-12-04 |
2024-03-28 |
Dyne Therapeutics, Inc. |
Antibody-oligonucleotide complexes and uses thereof
|
|
CA3202826A1
(en)
|
2020-12-31 |
2022-07-07 |
Duncan Brown |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
CA3202832A1
(en)
|
2020-12-31 |
2022-07-07 |
Romesh R. Subramanian |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US20250243244A1
(en)
|
2021-03-31 |
2025-07-31 |
Entrada Therapeutics, Inc. |
Cyclic cell penetrating peptides
|
|
US20250302979A1
(en)
|
2021-04-02 |
2025-10-02 |
Avidity Biosciences, Inc. |
Antibody-oligonucleotide conjugate and antibody-peptide-oligonucleotide conjugate compositions and methods of inducing exon skipping
|
|
WO2022217366A1
(en)
|
2021-04-14 |
2022-10-20 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Modified oligonucleotides for the treatment of duchenne muscular dystrophy
|
|
CA3216839A1
(en)
|
2021-04-30 |
2022-11-03 |
Sarepta Therapeutics, Inc. |
Treatment methods for muscular dystrophy
|
|
US20240247259A1
(en)
|
2021-05-10 |
2024-07-25 |
Entrada Therapeutics, Inc. |
Compositions and methods for modulating gene expression
|
|
EP4359008A4
(en)
|
2021-06-21 |
2026-05-06 |
Dyne Therapeutics Inc |
MUSCLE TARGETTING COMPLEXES AND THEIR USE TO TREAT FRIEDREICH'S ATAXIA
|
|
EP4359534A1
(en)
|
2021-06-21 |
2024-05-01 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating pompe disease
|
|
AU2022298028A1
(en)
|
2021-06-23 |
2023-12-21 |
National Center Of Neurology And Psychiatry |
Combination of antisense oligomers
|
|
KR20240035824A
(ko)
|
2021-07-09 |
2024-03-18 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도
|
|
CN117980006A
(zh)
|
2021-07-09 |
2024-05-03 |
达因疗法公司 |
用于治疗肌养蛋白病的肌肉靶向复合物和制剂
|
|
US11771776B2
(en)
|
2021-07-09 |
2023-10-03 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US20240382513A1
(en)
|
2021-07-09 |
2024-11-21 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
|
|
WO2023283619A2
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
CA3226301A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
MX2024000494A
(es)
|
2021-07-09 |
2024-04-10 |
Dyne Therapeutics Inc |
Complejos dirigidos al tratamiento de musculos, y usos de los mismos para tratar distrofinopatías.
|
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
WO2023283615A1
(en)
|
2021-07-09 |
2023-01-12 |
Dynetherapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
IL309909A
(en)
|
2021-07-09 |
2024-03-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US11672872B2
(en)
|
2021-07-09 |
2023-06-13 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor antibody and uses thereof
|
|
WO2023283629A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations thereof for treating facioscapulohumeral muscular dystrophy
|
|
WO2023022229A1
(ja)
|
2021-08-19 |
2023-02-23 |
国立大学法人東京医科歯科大学 |
モルホリノ核酸を含む修飾ヘテロ核酸
|
|
US20240390508A1
(en)
|
2021-08-21 |
2024-11-28 |
Takeda Pharmaceutical Company Limited |
Human transferrin receptor binding peptide-drug conjugate
|
|
JP2024532465A
(ja)
|
2021-09-01 |
2024-09-05 |
エントラーダ セラピューティクス，インコーポレイティド |
デュシェンヌ型筋ジストロフィーにおいてエクソン４５をスキッピングするための組成物及び方法
|
|
AU2022345986A1
(en)
|
2021-09-16 |
2024-03-07 |
Dyne Therapeutics, Inc. |
Dosing of muscle targeting complexes for treating dystrophinopathies
|
|
CN118201640A
(zh)
|
2021-11-01 |
2024-06-14 |
达因疗法公司 |
用于治疗肌养蛋白病的肌肉靶向复合物
|
|
WO2023086864A1
(en)
|
2021-11-12 |
2023-05-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes for treating facioscapulohumeral muscular dystrophy
|
|
US20250250564A2
(en)
|
2021-12-22 |
2025-08-07 |
Sapreme Technologies B.V. |
Compositions comprising therapeutic nucleic acid and saponin for the treatment of muscle-wasting disorders
|
|
IL313731A
(en)
|
2021-12-22 |
2024-08-01 |
Sapreme Tech Bv |
Preparations containing nucleic acids and sponges aimed at treating muscle wasting diseases
|
|
KR20240121778A
(ko)
|
2021-12-22 |
2024-08-09 |
사프렘 테크놀로지스 비.브이. |
근육 소모 장애의 치료를 위한 표적화된 사포닌-핵산 접합체
|
|
US20250114464A1
(en)
|
2022-01-27 |
2025-04-10 |
The Governors Of The University Of Alberta |
Pre-mrna slice modulating peptide-conjugated antisense therapeutics for the treatment of diseases
|
|
WO2023154807A2
(en)
|
2022-02-09 |
2023-08-17 |
Locanabio, Inc. |
Compositions and methods for modulating pre-mrna splicing
|
|
US20250170259A1
(en)
|
2022-03-03 |
2025-05-29 |
Yale University |
Compositions and methods for delivering therapeutic polynucleotides for exon skipping
|
|
JP2025079347A
(ja)
|
2022-03-11 |
2025-05-22 |
日本新薬株式会社 |
キャリアペプチドが連結された核酸
|
|
JP2025509438A
(ja)
|
2022-03-17 |
2025-04-11 |
サレプタ セラピューティクス， インコーポレイテッド |
ホスホロジアミデートモルホリノオリゴマーコンジュゲート
|
|
US12071621B2
(en)
|
2022-04-05 |
2024-08-27 |
Avidity Biosciences, Inc. |
Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
|
|
US20250249117A1
(en)
|
2022-04-15 |
2025-08-07 |
Dyne Therapeutics, Inc. |
Dosing of muscle targeting complexes for treating myotonic dystrophy
|
|
EP4508091A1
(en)
|
2022-04-15 |
2025-02-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
WO2023201318A1
(en)
|
2022-04-15 |
2023-10-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating myotonic dystrophy
|
|
KR20250004770A
(ko)
|
2022-04-15 |
2025-01-08 |
다인 세라퓨틱스, 인크. |
근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제
|
|
IL317868A
(en)
|
2022-07-06 |
2025-02-01 |
Dyne Therapeutics Inc |
CNS targeting complexes and their uses
|
|
WO2024011135A2
(en)
|
2022-07-06 |
2024-01-11 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
JP2025533454A
(ja)
|
2022-09-21 |
2025-10-07 |
サレプタ セラピューティクス， インコーポレイテッド |
Ｄｍｄアンチセンスオリゴヌクレオチド介在性エクソンスキッピング効率
|
|
KR20250099717A
(ko)
|
2022-10-31 |
2025-07-02 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 dmd 유전자의 엑손 45를 스키핑하기 위한 그의 용도
|
|
WO2024112809A2
(en)
|
2022-11-21 |
2024-05-30 |
Pepgen Inc. |
Cell-penetrating peptides, conjugates thereof, and methods of their use
|
|
TW202440925A
(zh)
|
2023-01-10 |
2024-10-16 |
美商浩博生物醫藥有限公司 |
供使用之經修飾之多段式反義寡核苷酸
|
|
KR20250159196A
(ko)
|
2023-02-27 |
2025-11-10 |
다인 세라퓨틱스, 인크. |
근육내 섬유증의 진행을 억제하기 위한 방법 및 조성물
|
|
WO2025076486A1
(en)
|
2023-10-06 |
2025-04-10 |
Dyne Therapeutics, Inc. |
Biomarkers for repeat expansion diseases
|
|
WO2025147541A1
(en)
|
2024-01-02 |
2025-07-10 |
Dyne Therapeutics, Inc. |
Methods and compositions for treating myotonic dystrophy
|